Once daily CRF2 peptide agonist (COR-1167)
The daily subcutaneous administration of COR-1167 with an autoinjector during the high-risk, vulnerable 3-month period after an episode of inpatient or outpatient WHF bears the potential to enhance the recovery from WHF by restabilizing the patient during the decompensation phase and blocking further deterioration, therefore improving the prognosis and the quality of life of WHF patients. COR-1167 is expected to decrease the left atrial pressure, central venous pressure and improve the cardiac output. Clinical evidence has been reported with urocortin-2 (natural CRF2 ligand with 15 min half-life) in HF patients. Preclinical efficacy with COR-1167 (long acting peptide) has been demonstrated in rat and sheep heart failure models. COR-1167 is ready for First in Human.